Gene Signal outlines 'aggressive' three-year plan as it completes latest funding round
This article was originally published in Scrip
Executive Summary
Having completed its latest private funding round, Lausanne, Switzerland-based biotech firm, Gene Signal said it is set to embark on an 'aggressive' three-year clinical and commercialization plan for its angiogenesis therapies.